Abstracts tagged "Biologics"

Abstract Number: 2658 • 2018 ACR/ARHP Annual Meeting
Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients
Lin Xie¹, Furaha Kariburyo¹, Janvi Sah¹, Jennifer Lofland² and Nan Li³, ¹STATinMED Research Inc., Ann Arbor, MI, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes inflammation in connective tissues and can involve multiple organs systems. Lupus nephritis (LN) is…
Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Elliot Hepworth¹, Mohammad Movahedi², Emmanouil Rampakakis³, Reza Mirza¹, Arthur Lau⁴, Angela Cesta⁵, Janet E. Pope⁶ and Claire Bombardier⁷, ¹Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴50 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
Abstract Number: 1829 • 2018 ACR/ARHP Annual Meeting
Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis
Julia Manasson¹, Lu Yang², Gary E. Solomon¹, Soumya M. Reddy¹, Parvathy V. Girija¹, Andrea L. Neimann³, Leopoldo N. Segal⁴, Carles Ubeda⁵, Jose C. Clemente⁶ and Jose U. Scher⁷, ¹Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³Department of Dermatology, New York University School of Medicine, New York, NY, ⁴Department of Medicine, Division of Pulmonary and Critical Care, New York University School of Medicine, New York City, NY, ⁵Institute for Research in Public Health (FISABIO), Valencia, Spain, ⁶Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: The microbiome serves a number of important functions, including modulation of the immune system and protection from pathogenic microorganisms1. Many autoimmune diseases have been…
Abstract Number: 2530 • 2018 ACR/ARHP Annual Meeting
Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
Zachary Schwartz¹, Jenny Schulz¹, Angelique Vinther¹, Alyce Kuklinski¹ and Kenneth Saag², ¹Clinical Care Options, Reston, VA, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biosimilar agents have changed the clinical landscape in rheumatology, gastroenterology, and dermatology. We sought to measure clinicians’ competence and knowledge of biosimilars and to…
Abstract Number: 2671 • 2018 ACR/ARHP Annual Meeting
Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment
Laurence E Cheng¹, Hailing Hsu², Martin Kankam³, Nicholas Siebers⁴, Randall Stoltz⁵, Lubna Abuqayyas², Bella Ertik⁶, Barbara Sullivan², Lei Zhou² and Jane R Parnes², ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS, ⁴Covance, Madison, WI, ⁵Covance, Evansville, IN, ⁶Amgen Inc, Boston, MA
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. AMG 570 is a bispecific molecule targeting…
Abstract Number: 636 • 2018 ACR/ARHP Annual Meeting
Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
Laure Gossec^1,2, Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz E. Joven⁶, Tatiana Korotaeva⁷, Michael Nurmohamed^8,9, Petros Sfikakis¹⁰, Stefan Siebert¹¹, Pavel Smirnov¹², Elke Theander¹³ and Josef S. Smolen¹⁴, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Sorbonne Université, Paris, France, ³Biometrics, Janssen-Cilag B.V., Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ⁸Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ¹⁰Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ¹¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Cardiff, United Kingdom, ¹²Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation, ¹³Biometrics, Janssen-Cilag B.V., Solna, Sweden, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: The link between treatment recommendations for PsA (to aim for a state of remission or low disease activity (LDA))1,2 and patient-important outcomes has been…
Abstract Number: 1840 • 2018 ACR/ARHP Annual Meeting
Disease Activity in Rheumatoid Arthritis Patients Is Influenced By Countries’ Socioeconomics: Results from the Meteor Registry
Sytske Anne Bergstra¹, José Tavares Costa², David Vega-Morales³, Karen Salomon-Escoto⁴, Nimmisha Govind⁵, Cornelia F. Allaart¹ and Robert B.M. Landewé⁶, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ³Rheumatology, University Hospital “Dr. José Eleuterio González”, UANL, Monterrey, Mexico, ⁴University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁵University of the Witwatersrand, Johannesburg, South Africa, ⁶Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: The treatment and prognosis of rheumatoid arthritis (RA) patients have improved tremendously, but patients across the world may not benefit similarly. One of the…
Abstract Number: 2533 • 2018 ACR/ARHP Annual Meeting
Switching Patients with Arthritis from Etanercept (Enbrel) to the Biosimilar Drug, Benepali: A Single- Center Retrospective Observational Study
Anastasia- Vasiliki Madenidou¹, Andrew Jeffries², Sneha Varughese², Stephen Jones², Helen Veevers², Hanadi Sari- Kouzel² and Chandini Rao², ¹Rheumatology, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom, ²Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
Background/Purpose: Benepali, the etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel.In 2016, the Rheumatology Department at Blackpool…
Abstract Number: 2821 • 2018 ACR/ARHP Annual Meeting
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Cecilie Heegaard Brahe¹, Simon Krabbe¹, Mikkel Østergaard¹, Lykke Midtbøll Ørnbjerg¹, Daniel Glinatsi¹, Henrik Rogind¹, Hanne Slott Jensen², Annette Hansen³, Jesper Nørregaard⁴, Søren Jacobsen⁵, Lene Terslev¹, Tuan Khai Huynh⁴, Dorte Vendelbo Jensen⁶, Natalia Manilo², Karsten Asmussen², Per Brown-Frandsen⁵, Mikael Boesen⁷, Zoreh Rastiemadabadi⁷, Lone Morsel-Carlsen⁷, Jakob M. Møller⁸, Niels Steen Krogh⁹ and Merete Lund Hetland¹⁰, ¹Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ²Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, Hillerød, Denmark, ⁵Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁸Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, ¹⁰DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors Background/Purpose: A cohort of routine care…
Abstract Number: 662 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab for up to 3 Years
Désirée van der Heijde¹, Vinod Chandran², Roy Fleischmann³, Olivier Benichou⁴, Suchitrita Rathmann⁴ and Catherine Shuler⁴, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, was shown to be superior to placebo (PBO) in inhibiting the progression of structural joint damage in patients (pts)…
Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Johan Askling², Adrian Ciurea³, Eirik K Kristianslund⁴, Fatos Onen⁵, Dan Nordström⁶, Maria José Santos⁷, Catalin Codreanu⁸, Ziga Rotar⁹, Björn Gudbjornsson¹⁰, Daniela Di Giuseppe², Michael J. Nissen¹¹, Tore Kvien⁴, Merih Birlik⁵, Nina Trokovic⁶, Anabela Barcelos⁷, Ruxandra Ionescu⁸, Matija Tomšič⁹, Arni Jon Geirsson¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Tamara Rusman¹³, Juan J. Gomez-Reino¹⁴, Gareth T. Jones¹⁵, Florenzo Iannone¹⁶, Karel Pavelka¹², Irene van der Horst-Bruinsma¹⁷, Lise Hyldstrup¹, Niels Steen Krogh¹⁸, Merete Lund Hetland¹ and Mikkel Østergaard¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Zurich, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁸RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ⁹biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ¹⁰ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ¹¹SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Haarlem, Netherlands, ¹⁴BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁵BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁶GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁷ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁸Zitelab, EuroSpA Research Collaboration Network, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…
Abstract Number: 2549 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
Vibeke Strand¹, Matthew Reaney², Erin Mangan³, Hubert van Hoogstraten⁴, Susan Boklage³ and Chih-Chi Hu⁵, ¹Stanford University School of Medicine, Palo Alto, CA, ²Sanofi, Guildford, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab is a human monoclonal antibody that binds to membrane and soluble IL-6R, which is approved for the treatment of moderate to severe rheumatoid…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 684 • 2018 ACR/ARHP Annual Meeting
Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials
Frank Behrens¹, Peter Nash², Laure Gossec³, Soyi Liu Leage⁴, Inmaculada de la Torre⁵, Christophe Sapin⁴, Monika Kurzawa⁶, Gerd R. Burmester⁷ and Josef S. Smolen⁸, ¹Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ²University of Queensland, Brisbane, Australia, ³Sorbonne Universités, Paris, France, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company, Madrid, Spain, ⁶Eli Lilly and Company, Bad Homburg, Germany, ⁷Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, ⁸Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is a highly heterogeneous chronic inflammatory disease combining a range of musculoskeletal and extra-articular manifestations. Ixekizumab (IXE) is approved for the treatment of…
Abstract Number: 2038 • 2018 ACR/ARHP Annual Meeting
Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis
Satoshi Kubo¹, Shingo Nakayamada¹, Yusuke Miyazaki¹, Maiko Yoshikawa², Hiroko Yoshinari³, Shigeru Iwata⁴, Kentaro Hanami², Shunsuke Fukuyo³, Ippei Miyagawa⁵, Kazuhisa Nakano¹ and Yoshiya Tanaka⁶, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), molecular targeted therapies induced different changes in different immune cell phenotypes. For instance, our previous study showed…

« Previous Page
1
…
5
6
7
8
9
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].